Nanotechnological approaches in prostate cancer therapy: Integration of engineering and biology

Basit Öğe Kaydı
dc.authoridAli Zarrabi / 0000-0003-0391-1769en_US
dc.authorscopusidAli Zarrabi / 23483174100en_US
dc.authorwosidAli Zarrabi / U-2602-2019
dc.contributor.authorAshrafizadeh, Milad
dc.contributor.authorAghamiri, Shahin
dc.contributor.authorTan, Shing Cheng
dc.contributor.authorZarrabi, Ali
dc.contributor.authorSharifi, Esmaeel
dc.date.accessioned2022-07-26T12:14:56Z
dc.date.available2022-07-26T12:14:56Z
dc.date.issued2022en_US
dc.departmentİstinye Üniversitesi, Mühendislik ve Doğa Bilimleri Fakültesi, Biyomedikal Mühendisliği Bölümüen_US
dc.description.abstractNanocarriers have received special attention in biomedicine for the treatment of various diseases, especially cancer, as one of the leading causes of death worldwide. Nanocarriers can improve the potential of contemporary strategies in cancer therapy and also provide new methods for diagnosis and biosensing. The present review focuses on the biomedical application of nanocarriers in the treatment of prostate cancer (PCa), one of the most common urological cancers in men. The chemotherapeutic and radiotherapeutic potentials in PCa may be improved using nanocarriers by providing targeted drug delivery and inducing PCa cells' sensitivity via induction of cell death. Delivery of nucleic acid drugs such as siRNA, shRNA and CRISPR/Cas9 system by nanocarriers in PCa therapy enhances the intracellular accumulation of these therapeutics and increases their efficacy in gene expression regulation. The high proliferation rate and metastasis of PCa cells result in poor prognosis. They may be dually suppressed by nanocarriers, as nanoplatforms facilitate co-delivery of drugs and gene therapeutics in PCa suppression. Selectivity toward PCa cells may be enhanced via surface modification of the nanocarriers to facilitate internalization via endocytosis. In addition to their applications for PCa treatment, nanocarriers mediate the detection of biomarkers for PCa diagnosis. © 2022 Elsevier Ltden_US
dc.identifier.citationAshrafizadeh, M., Aghamiri, S., Tan, S. C., Zarrabi, A., Sharifi, E., Rabiee, N., . . . Wang, Y. (2022). Nanotechnological approaches in prostate cancer therapy: Integration of engineering and biology. Nano Today, 45 doi:10.1016/j.nantod.2022.101532en_US
dc.identifier.doi10.1016/j.nantod.2022.101532en_US
dc.identifier.issn1748-0132en_US
dc.identifier.scopus2-s2.0-85134290793en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.urihttps://doi.org/10.1016/j.nantod.2022.101532
dc.identifier.urihttps://hdl.handle.net/20.500.12713/3055
dc.identifier.volume45en_US
dc.identifier.wosWOS:000835571100002en_US
dc.identifier.wosqualityQ1en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.institutionauthorZarrabi, Ali
dc.language.isoenen_US
dc.publisherElsevier B.V.en_US
dc.relation.ispartofNano Todayen_US
dc.relation.publicationcategoryDiğeren_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectCancer Diagnosisen_US
dc.subjectDrug Sensitivityen_US
dc.subjectGene Deliveryen_US
dc.subjectProstate Canceren_US
dc.subjectSurface Modificationen_US
dc.subjectTherapeutic Responseen_US
dc.titleNanotechnological approaches in prostate cancer therapy: Integration of engineering and biologyen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
1-s2.0-S1748013222001591-main.pdf
Boyut:
25.07 MB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu